ROIV

Roivant Sciences Ltd.

A biopharmaceutical company that develops experimental drugs for autoimmune and rare diseases through a family of nimble subsidiaries it calls 'Vants' — including Immunovant, Priovant, and Pulmovant — each focused on a specific drug candidate. Founded in 2014 by entrepreneur Vivek Ramaswamy, the name blends 'ROI' (return on investment) with the '-vant' suffix stamped on every subsidiary. Its most advanced candidate, brepocitinib, is under FDA review for the rare muscle disease dermatomyositis.

CINS: G76279101CUSIP: G76279101HealthcareUS3 holders

Ownership Activity Financials Filings

ROIV

ROIV

Regulation FD Disclosure

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Regulation FD Disclosure